Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215130 | 0.77 | — | — | |
| SCHEMBL13644805 | 0.77 | KMT2A (0.46) | CHRM2CHRM1 | |
| SCHEMBL1267148 | 0.65 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL8510084 | 0.65 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL8597287 | 0.62 | CHRM2 (0.36) | CHRM2CHRM1 | |
| SCHEMBL13865535 | 0.62 | CHRM2 (0.36) | CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL14841752 | 0.61 | CHRM2 (0.35) | CHRM2CHRM1 | |
| SCHEMBL16302321 | 0.61 | — | — | |
| SCHEMBL15148192 | 0.60 | CHRM2 (0.34) | CHRM2CHRM1 | |
| SCHEMBL3220364 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | CHRM2 4872/4885CHRM1 4832/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | CHRM2 3702/4885CHRM1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.